TGFBR2 and GOPC |
transforming growth factor, beta receptor II (70/80kDa) |
golgi-associated PDZ and coiled-coil motif containing |
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- SMAD2/3 MH2 Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
|
TGFBR2 and STRAP |
transforming growth factor, beta receptor II (70/80kDa) |
serine/threonine kinase receptor associated protein |
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- SMAD2/3 MH2 Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- Downregulation of TGF-beta receptor signaling
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGFBR1 KD Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
TGFBR2 and ARHGEF7 |
transforming growth factor, beta receptor II (70/80kDa) |
Rho guanine nucleotide exchange factor (GEF) 7 |
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- SMAD2/3 MH2 Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- EGFR downregulation
- Signaling by GPCR
- Signalling by NGF
- Axon guidance
- Cell death signalling via NRAGE, NRIF and NADE
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- p75 NTR receptor-mediated signalling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by EGFRvIII in Cancer
- Rho GTPase cycle
- Signaling by EGFR
- GPCR downstream signaling
- Ephrin signaling
- NRAGE signals death through JNK
- Signaling by Rho GTPases
- Signaling by EGFR in Cancer
- EPH-Ephrin signaling
- G alpha (12/13) signalling events
|
|
|
|
|
A1BG and CDKN1A |
alpha-1-B glycoprotein |
cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Cellular Senescence
- p53-Dependent G1/S DNA damage checkpoint
- Cyclin E associated events during G1/S transition
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- PI-3K cascade
- G1/S Transition
- Removal of licensing factors from origins
- Switching of origins to a post-replicative state
- Mitotic G1-G1/S phases
- Signaling by PDGF
- DAP12 interactions
- DNA Damage/Telomere Stress Induced Senescence
- GAB1 signalosome
- Senescence-Associated Secretory Phenotype (SASP)
- S Phase
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- SCF(Skp2)-mediated degradation of p27/p21
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Cyclin A:Cdk2-associated events at S phase entry
- SCF(Skp2)-mediated degradation of p27/p21
- Adaptive Immune System
- PIP3 activates AKT signaling
- Orc1 removal from chromatin
- p53-Dependent G1 DNA Damage Response
- PI3K events in ERBB2 signaling
- Transcriptional activation of p53 responsive genes
- Downstream signaling of activated FGFR
- G1/S DNA Damage Checkpoints
- Innate Immune System
- Transcriptional activation of cell cycle inhibitor p21
- Signalling by NGF
- Synthesis of DNA
- G1 Phase
- Regulation of DNA replication
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell Cycle, Mitotic
- Signaling by FGFR
- Orc1 removal from chromatin
- Cyclin D associated events in G1
- Cell Cycle Checkpoints
|
|
|
|
|
A2M and CDKN1A |
alpha-2-macroglobulin |
cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
- Lipoprotein metabolism
- Metabolism of lipids and lipoproteins
- Platelet degranulation
- Lipid digestion, mobilization, and transport
- Degradation of the extracellular matrix
- Formation of Fibrin Clot (Clotting Cascade)
- Rho GTPase cycle
- Intrinsic Pathway
- HDL-mediated lipid transport
- Response to elevated platelet cytosolic Ca2+
- Signaling by Rho GTPases
- Platelet activation, signaling and aggregation
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Cellular Senescence
- p53-Dependent G1/S DNA damage checkpoint
- Cyclin E associated events during G1/S transition
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- PI-3K cascade
- G1/S Transition
- Removal of licensing factors from origins
- Switching of origins to a post-replicative state
- Mitotic G1-G1/S phases
- Signaling by PDGF
- DAP12 interactions
- DNA Damage/Telomere Stress Induced Senescence
- GAB1 signalosome
- Senescence-Associated Secretory Phenotype (SASP)
- S Phase
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- SCF(Skp2)-mediated degradation of p27/p21
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Cyclin A:Cdk2-associated events at S phase entry
- SCF(Skp2)-mediated degradation of p27/p21
- Adaptive Immune System
- PIP3 activates AKT signaling
- Orc1 removal from chromatin
- p53-Dependent G1 DNA Damage Response
- PI3K events in ERBB2 signaling
- Transcriptional activation of p53 responsive genes
- Downstream signaling of activated FGFR
- G1/S DNA Damage Checkpoints
- Innate Immune System
- Transcriptional activation of cell cycle inhibitor p21
- Signalling by NGF
- Synthesis of DNA
- G1 Phase
- Regulation of DNA replication
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell Cycle, Mitotic
- Signaling by FGFR
- Orc1 removal from chromatin
- Cyclin D associated events in G1
- Cell Cycle Checkpoints
|
- Becaplermin
- Bacitracin
- Ocriplasmin
|
|
|
|
ACACA and BRCA1 |
acetyl-CoA carboxylase alpha |
breast cancer 1, early onset |
- Metabolism of vitamins and cofactors
- Defective CD320 causes methylmalonic aciduria
- Defective LMBRD1 causes methylmalonic aciduria and homocystinuria type cblF
- Integration of energy metabolism
- Metabolism of lipids and lipoproteins
- ChREBP activates metabolic gene expression
- Defective BTD causes biotidinase deficiency
- Import of palmitoyl-CoA into the mitochondrial matrix
- Defective MMACHC causes methylmalonic aciduria and homocystinuria type cblC
- Defective MTR causes methylmalonic aciduria and homocystinuria type cblG
- Defective MTRR causes methylmalonic aciduria and homocystinuria type cblE
- Regulation of cholesterol biosynthesis by SREBP (SREBF)
- Fatty Acyl-CoA Biosynthesis
- Defective AMN causes hereditary megaloblastic anemia 1
- Triglyceride Biosynthesis
- Defects in cobalamin (B12) metabolism
- Defective GIF causes intrinsic factor deficiency
- Fatty acid, triacylglycerol, and ketone body metabolism
- Defective HLCS causes multiple carboxylase deficiency
- Defective MMAB causes methylmalonic aciduria type cblB
- Defective MMADHC causes methylmalonic aciduria and homocystinuria type cblD
- Defective MMAA causes methylmalonic aciduria type cblA
- Defective CUBN causes hereditary megaloblastic anemia 1
- Metabolism of water-soluble vitamins and cofactors
- Defective MUT causes methylmalonic aciduria mut type
- Defects in biotin (Btn) metabolism
- Activation of gene expression by SREBF (SREBP)
- Defective TCN2 causes hereditary megaloblastic anemia
- Biotin transport and metabolism
- Defects in vitamin and cofactor metabolism
|
- ATM mediated phosphorylation of repair proteins
- Meiotic recombination
- Fanconi Anemia pathway
- ATM mediated response to DNA double-strand break
- Homologous Recombination Repair
- Meiotic synapsis
- Homologous recombination repair of replication-independent double-strand breaks
- Recruitment of repair and signaling proteins to double-strand breaks
- Double-Strand Break Repair
|
|
|
|
|
ACTB and CDKN1A |
actin, beta |
cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
- Axon guidance
- Gap junction degradation
- Adherens junctions interactions
- Translocation of GLUT4 to the plasma membrane
- L1CAM interactions
- Recycling pathway of L1
- HATs acetylate histones
- VEGFA-VEGFR2 Pathway
- EPHB-mediated forward signaling
- Interaction between L1 and Ankyrins
- Cell-cell junction organization
- EPH-ephrin mediated repulsion of cells
- Prefoldin mediated transfer of substrate to CCT/TriC
- Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding
- Gap junction trafficking and regulation
- EPH-Ephrin signaling
- Fcgamma receptor (FCGR) dependent phagocytosis
- Regulation of actin dynamics for phagocytic cup formation
- Folding of actin by CCT/TriC
- Innate Immune System
- Cell junction organization
- Protein folding
- Formation of annular gap junctions
- Chromatin organization
- Gap junction trafficking
- Factors involved in megakaryocyte development and platelet production
- Chromatin modifying enzymes
- Signaling by VEGF
- Chaperonin-mediated protein folding
- Cell-extracellular matrix interactions
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Cellular Senescence
- p53-Dependent G1/S DNA damage checkpoint
- Cyclin E associated events during G1/S transition
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- PI-3K cascade
- G1/S Transition
- Removal of licensing factors from origins
- Switching of origins to a post-replicative state
- Mitotic G1-G1/S phases
- Signaling by PDGF
- DAP12 interactions
- DNA Damage/Telomere Stress Induced Senescence
- GAB1 signalosome
- Senescence-Associated Secretory Phenotype (SASP)
- S Phase
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- SCF(Skp2)-mediated degradation of p27/p21
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Cyclin A:Cdk2-associated events at S phase entry
- SCF(Skp2)-mediated degradation of p27/p21
- Adaptive Immune System
- PIP3 activates AKT signaling
- Orc1 removal from chromatin
- p53-Dependent G1 DNA Damage Response
- PI3K events in ERBB2 signaling
- Transcriptional activation of p53 responsive genes
- Downstream signaling of activated FGFR
- G1/S DNA Damage Checkpoints
- Innate Immune System
- Transcriptional activation of cell cycle inhibitor p21
- Signalling by NGF
- Synthesis of DNA
- G1 Phase
- Regulation of DNA replication
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell Cycle, Mitotic
- Signaling by FGFR
- Orc1 removal from chromatin
- Cyclin D associated events in G1
- Cell Cycle Checkpoints
|
|
|
|
|
ACTL6A and MYC |
actin-like 6A |
v-myc avian myelocytomatosis viral oncogene homolog |
- Chromatin modifying enzymes
- Chromatin organization
- HATs acetylate histones
- RMTs methylate histone arginines
|
- Loss of Function of TGFBR2 in Cancer
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Signaling by Wnt
- Cyclin E associated events during G1/S transition
- binding of TCF/LEF:CTNNB1 to target gene promoters
- TGFBR1 LBD Mutants in Cancer
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Generic Transcription Pathway
- RNF mutants show enhanced WNT signaling and proliferation
- G1/S Transition
- Signaling by NOTCH1
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Mitotic G1-G1/S phases
- FBXW7 Mutants and NOTCH1 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Loss of Function of SMAD2/3 in Cancer
- Signaling by NOTCH
- formation of the beta-catenin:TCF transactivating complex
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- S Phase
- Cell Cycle, Mitotic
- Loss of Function of TGFBR1 in Cancer
- NOTCH1 Intracellular Domain Regulates Transcription
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- TCF dependent signaling in response to WNT
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Cyclin A:Cdk2-associated events at S phase entry
- Signaling by WNT in cancer
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
ACTN1 and APC |
actinin, alpha 1 |
adenomatous polyposis coli |
- Cell junction organization
- Syndecan interactions
- Response to elevated platelet cytosolic Ca2+
- Regulation of cytoskeletal remodeling and cell spreading by IPP complex components
- Nephrin interactions
- Platelet degranulation
- Non-integrin membrane-ECM interactions
- Platelet activation, signaling and aggregation
- Cell-extracellular matrix interactions
|
- misspliced GSK3beta mutants stabilize beta-catenin
- APC truncation mutants have impaired AXIN binding
- T41 mutants of beta-catenin aren't phosphorylated
- truncated APC mutants destabilize the destruction complex
- TCF7L2 mutants don't bind CTBP
- Signaling by Wnt
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- Degradation of beta-catenin by the destruction complex
- RNF mutants show enhanced WNT signaling and proliferation
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- S33 mutants of beta-catenin aren't phosphorylated
- XAV939 inhibits tankyrase, stabilizing AXIN
- Programmed Cell Death
- Beta-catenin phosphorylation cascade
- truncations of AMER1 destabilize the destruction complex
- Apoptotic cleavage of cellular proteins
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Apoptotic execution phase
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- deletions in the AMER1 gene destabilize the destruction complex
- TCF dependent signaling in response to WNT
- AMER1 mutants destabilize the destruction complex
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
|
|
|
|
|
ACVR1 and TGFBR2 |
activin A receptor, type I |
transforming growth factor, beta receptor II (70/80kDa) |
|
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- SMAD2/3 MH2 Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Adenosine triphosphate
- 6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine
|
|
|
|
ACVRL1 and TGFBR2 |
activin A receptor type II-like 1 |
transforming growth factor, beta receptor II (70/80kDa) |
|
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- SMAD2/3 MH2 Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
ADH6 and KRAS |
alcohol dehydrogenase 6 (class V) |
Kirsten rat sarcoma viral oncogene homolog |
- Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B)
- Defective FMO3 causes Trimethylaminuria (TMAU)
- Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD)
- Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)
- Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX)
- Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4)
- Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA)
- Ethanol oxidation
- Metabolic disorders of biological oxidation enzymes
- Defective CYP1B1 causes Glaucoma
- Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A)
- Phase 1 - Functionalization of compounds
- Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5)
- Defective CYP19A1 causes Aromatase excess syndrome (AEXS)
- Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3)
- Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)
- Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4)
- Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)
- Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)
- Defective MAOA causes Brunner syndrome (BRUNS)
- Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency)
- Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3)
- Biological oxidations
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- SHC-mediated cascade
- MEK activation
- FCERI mediated MAPK activation
- Signaling by EGFRvIII in Cancer
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Gastrin-CREB signalling pathway via PKC and MAPK
- p38MAPK events
- SOS-mediated signalling
- SHC-mediated signalling
- Signaling by PDGF
- DAP12 interactions
- SHC-related events triggered by IGF1R
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Signaling by VEGF
- Downstream signal transduction
- Signalling to RAS
- Signaling by FGFR mutants
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Interleukin-2 signaling
- Frs2-mediated activation
- Signaling by Leptin
- Adaptive Immune System
- Signalling to ERKs
- Prolonged ERK activation events
- Axon guidance
- IRS-mediated signalling
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- IRS-related events triggered by IGF1R
- EGFR Transactivation by Gastrin
- GRB2 events in ERBB2 signaling
- VEGFR2 mediated cell proliferation
- RAF phosphorylates MEK
- Downstream signaling of activated FGFR
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Signaling by Insulin receptor
- Innate Immune System
- Signalling by NGF
- Insulin receptor signalling cascade
- SOS-mediated signalling
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- SHC-related events
- NGF signalling via TRKA from the plasma membrane
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- ARMS-mediated activation
- RAF activation
- SHC1 events in EGFR signaling
- IRS-mediated signalling
- Activation of RAS in B cells
- FRS2-mediated cascade
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Constitutive Signaling by EGFRvIII
|
|
|
|
|
PARP1 and RNF146 |
poly (ADP-ribose) polymerase 1 |
ring finger protein 146 |
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGFBR1 KD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- TGFBR1 LBD Mutants in Cancer
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Loss of Function of TGFBR1 in Cancer
- Generic Transcription Pathway
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- SMAD4 MH2 Domain Mutants in Cancer
|
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- XAV939 inhibits tankyrase, stabilizing AXIN
- degradation of AXIN
- Signaling by Wnt
- Signaling by WNT in cancer
|
- Carba-Nicotinamide-Adenine-Dinucleotide
- NU1025
- Nicotinamide
- 2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone
- 3-Methoxybenzamide
- 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide
- 3,4-Dihydro-5-Methyl-Isoquinolinone
- 2-(3\'-Methoxyphenyl) Benzimidazole-4-Carboxamide
- 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE
- (2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium
- trans-4-(7-carbamoyl-1H-benzimidazol-2-yl)-1-propylpiperidinium
- 5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE
|
|
|
|
ADRBK1 and EGF |
adrenergic, beta, receptor kinase 1 |
epidermal growth factor |
- G alpha (q) signalling events
- Ca-dependent events
- Signaling by GPCR
- CaM pathway
- Phospholipase C-mediated cascade
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- DAG and IP3 signaling
- CaM pathway
- DAP12 signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- Hedgehog 'on' state
- Downstream signaling of activated FGFR
- Innate Immune System
- Signaling by PDGF
- Calmodulin induced events
- Signalling by NGF
- DAP12 interactions
- PLC beta mediated events
- Opioid Signalling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- G-protein mediated events
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- G alpha (q) signalling events
- Signaling by EGFR
- GPCR downstream signaling
- Calmodulin induced events
- Downstream signal transduction
- PLC-gamma1 signalling
- Signaling by Hedgehog
- Signaling by EGFR in Cancer
- Activation of SMO
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- PIP3 activates AKT signaling
- Platelet degranulation
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- Signaling by SCF-KIT
- SHC1 events in ERBB2 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- GRB2 events in ERBB2 signaling
- PI-3K cascade
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Response to elevated platelet cytosolic Ca2+
- Innate Immune System
- Signaling by PDGF
- EGFR downregulation
- Signalling by NGF
- DAP12 interactions
- GAB1 signalosome
- GRB2 events in EGFR signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by ERBB4
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Inhibition of Signaling by Overexpressed EGFR
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- Signaling by EGFR
- SHC1 events in EGFR signaling
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Constitutive Signaling by EGFRvIII
- Platelet activation, signaling and aggregation
- Adaptive Immune System
|
|
- Sucralfate
- Alpha-Aminobutyric Acid
|
|
|
ADRBK1 and MDM2 |
adrenergic, beta, receptor kinase 1 |
MDM2 proto-oncogene, E3 ubiquitin protein ligase |
- G alpha (q) signalling events
- Ca-dependent events
- Signaling by GPCR
- CaM pathway
- Phospholipase C-mediated cascade
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- DAG and IP3 signaling
- CaM pathway
- DAP12 signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- Hedgehog 'on' state
- Downstream signaling of activated FGFR
- Innate Immune System
- Signaling by PDGF
- Calmodulin induced events
- Signalling by NGF
- DAP12 interactions
- PLC beta mediated events
- Opioid Signalling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- G-protein mediated events
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- G alpha (q) signalling events
- Signaling by EGFR
- GPCR downstream signaling
- Calmodulin induced events
- Downstream signal transduction
- PLC-gamma1 signalling
- Signaling by Hedgehog
- Signaling by EGFR in Cancer
- Activation of SMO
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Cellular Senescence
- p53-Dependent G1/S DNA damage checkpoint
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- PI-3K cascade
- Stabilization of p53
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- Transmission across Chemical Synapses
- PIP3 activates AKT signaling
- Oncogene Induced Senescence
- p53-Dependent G1 DNA Damage Response
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- G1/S DNA Damage Checkpoints
- Innate Immune System
- Signalling by NGF
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Trafficking of AMPA receptors
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- Oxidative Stress Induced Senescence
- Cell Cycle Checkpoints
- Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
|
|
- Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
- Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
|
|
|
ADRBK1 and EGFR |
adrenergic, beta, receptor kinase 1 |
epidermal growth factor receptor |
- G alpha (q) signalling events
- Ca-dependent events
- Signaling by GPCR
- CaM pathway
- Phospholipase C-mediated cascade
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- DAG and IP3 signaling
- CaM pathway
- DAP12 signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- Hedgehog 'on' state
- Downstream signaling of activated FGFR
- Innate Immune System
- Signaling by PDGF
- Calmodulin induced events
- Signalling by NGF
- DAP12 interactions
- PLC beta mediated events
- Opioid Signalling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- G-protein mediated events
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- G alpha (q) signalling events
- Signaling by EGFR
- GPCR downstream signaling
- Calmodulin induced events
- Downstream signal transduction
- PLC-gamma1 signalling
- Signaling by Hedgehog
- Signaling by EGFR in Cancer
- Activation of SMO
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K/AKT activation
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by PDGF
- EGFR downregulation
- DAP12 interactions
- GAB1 signalosome
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- L1CAM interactions
- EGFR Transactivation by Gastrin
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signalling by NGF
- Signal transduction by L1
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Inhibition of Signaling by Overexpressed EGFR
- Signaling by FGFR
- SHC1 events in EGFR signaling
- Constitutive Signaling by EGFRvIII
|
|
- Cetuximab
- Trastuzumab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Flavopiridol
- Vandetanib
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- Afatinib
|
|
|
AP2A1 and SHC1 |
adaptor-related protein complex 2, alpha 1 subunit |
SHC (Src homology 2 domain containing) transforming protein 1 |
- Trafficking of GluR2-containing AMPA receptors
- Retrograde neurotrophin signalling
- Axon guidance
- HIV Infection
- Nef Mediated CD8 Down-regulation
- L1CAM interactions
- Signaling by Wnt
- Signaling by EGFRvIII in Cancer
- Recycling pathway of L1
- EPH-ephrin mediated repulsion of cells
- MHC class II antigen presentation
- EPH-Ephrin signaling
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Nef Mediated CD4 Down-regulation
- EGFR downregulation
- Signalling by NGF
- Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
- Host Interactions of HIV factors
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- The role of Nef in HIV-1 replication and disease pathogenesis
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Trafficking of AMPA receptors
- beta-catenin independent WNT signaling
- Signaling by EGFR
- WNT5A-dependent internalization of FZD4
- Signaling by EGFR in Cancer
- Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
- PCP/CE pathway
- Adaptive Immune System
- Transmission across Chemical Synapses
|
- Signaling by GPCR
- Signaling by EGFRvIII in Cancer
- Platelet Aggregation (Plug Formation)
- SHC1 events in ERBB2 signaling
- IRE1alpha activates chaperones
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Interleukin receptor SHC signaling
- SHC-mediated signalling
- G-protein beta:gamma signalling
- SHC-related events triggered by IGF1R
- Signaling by ERBB4
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- GPCR downstream signaling
- SHC1 events in ERBB4 signaling
- Signalling to RAS
- Signaling by EGFR in Cancer
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Signalling to ERKs
- IGF1R signaling cascade
- XBP1(S) activates chaperone genes
- G beta:gamma signalling through PI3Kgamma
- Unfolded Protein Response (UPR)
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- SHC-mediated signalling
- Integrin alphaIIb beta3 signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- SHC-related events
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- SHC1 events in EGFR signaling
- Signal attenuation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Constitutive Signaling by EGFRvIII
- SHC activation
|
|
|
|
|
AP2A2 and SHC1 |
adaptor-related protein complex 2, alpha 2 subunit |
SHC (Src homology 2 domain containing) transforming protein 1 |
- Retrograde neurotrophin signalling
- Axon guidance
- HIV Infection
- Nef Mediated CD8 Down-regulation
- L1CAM interactions
- Signaling by Wnt
- Signaling by EGFRvIII in Cancer
- Recycling pathway of L1
- EPH-ephrin mediated repulsion of cells
- MHC class II antigen presentation
- EPH-Ephrin signaling
- Nef Mediated CD4 Down-regulation
- EGFR downregulation
- Signalling by NGF
- Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
- Host Interactions of HIV factors
- The role of Nef in HIV-1 replication and disease pathogenesis
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- beta-catenin independent WNT signaling
- Signaling by EGFR
- WNT5A-dependent internalization of FZD4
- Signaling by EGFR in Cancer
- PCP/CE pathway
- Adaptive Immune System
|
- Signaling by GPCR
- Signaling by EGFRvIII in Cancer
- Platelet Aggregation (Plug Formation)
- SHC1 events in ERBB2 signaling
- IRE1alpha activates chaperones
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Interleukin receptor SHC signaling
- SHC-mediated signalling
- G-protein beta:gamma signalling
- SHC-related events triggered by IGF1R
- Signaling by ERBB4
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- GPCR downstream signaling
- SHC1 events in ERBB4 signaling
- Signalling to RAS
- Signaling by EGFR in Cancer
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Signalling to ERKs
- IGF1R signaling cascade
- XBP1(S) activates chaperone genes
- G beta:gamma signalling through PI3Kgamma
- Unfolded Protein Response (UPR)
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- SHC-mediated signalling
- Integrin alphaIIb beta3 signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- SHC-related events
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- SHC1 events in EGFR signaling
- Signal attenuation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Constitutive Signaling by EGFRvIII
- SHC activation
|
|
|
|
|
AP2B1 and APC |
adaptor-related protein complex 2, beta 1 subunit |
adenomatous polyposis coli |
- Retrograde neurotrophin signalling
- Axon guidance
- HIV Infection
- Nef Mediated CD8 Down-regulation
- L1CAM interactions
- Signaling by Wnt
- Signaling by EGFRvIII in Cancer
- Recycling pathway of L1
- EPH-ephrin mediated repulsion of cells
- MHC class II antigen presentation
- EPH-Ephrin signaling
- Nef Mediated CD4 Down-regulation
- EGFR downregulation
- Signalling by NGF
- Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
- Host Interactions of HIV factors
- The role of Nef in HIV-1 replication and disease pathogenesis
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- beta-catenin independent WNT signaling
- Signaling by EGFR
- WNT5A-dependent internalization of FZD4
- Signaling by EGFR in Cancer
- PCP/CE pathway
- Adaptive Immune System
|
- misspliced GSK3beta mutants stabilize beta-catenin
- APC truncation mutants have impaired AXIN binding
- T41 mutants of beta-catenin aren't phosphorylated
- truncated APC mutants destabilize the destruction complex
- TCF7L2 mutants don't bind CTBP
- Signaling by Wnt
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- Degradation of beta-catenin by the destruction complex
- RNF mutants show enhanced WNT signaling and proliferation
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- S33 mutants of beta-catenin aren't phosphorylated
- XAV939 inhibits tankyrase, stabilizing AXIN
- Programmed Cell Death
- Beta-catenin phosphorylation cascade
- truncations of AMER1 destabilize the destruction complex
- Apoptotic cleavage of cellular proteins
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Apoptotic execution phase
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- deletions in the AMER1 gene destabilize the destruction complex
- TCF dependent signaling in response to WNT
- AMER1 mutants destabilize the destruction complex
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
|
|
|
|
|
AP2B1 and SMAD4 |
adaptor-related protein complex 2, beta 1 subunit |
SMAD family member 4 |
- Retrograde neurotrophin signalling
- Axon guidance
- HIV Infection
- Nef Mediated CD8 Down-regulation
- L1CAM interactions
- Signaling by Wnt
- Signaling by EGFRvIII in Cancer
- Recycling pathway of L1
- EPH-ephrin mediated repulsion of cells
- MHC class II antigen presentation
- EPH-Ephrin signaling
- Nef Mediated CD4 Down-regulation
- EGFR downregulation
- Signalling by NGF
- Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
- Host Interactions of HIV factors
- The role of Nef in HIV-1 replication and disease pathogenesis
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- beta-catenin independent WNT signaling
- Signaling by EGFR
- WNT5A-dependent internalization of FZD4
- Signaling by EGFR in Cancer
- PCP/CE pathway
- Adaptive Immune System
|
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Signaling by BMP
- Transcriptional regulation of pluripotent stem cells
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|